@article{5e152242074f4a3ea2e88380a3e96b2d,
title = "State of the Art: Interventional Pulmonology",
abstract = "Interventional pulmonology (IP) has evolved over the past decade from an obscure subspecialty in pulmonary medicine to a recognized discipline offering advanced consultative and procedural services to patients with thoracic malignancy, anatomic airway disease, and pleural disease. Innovative interventions are now also available for diseases not traditionally treated procedurally, such as asthma and emphysema. The IP field has established certification examinations and training standards for IP training programs in an effort to enhance training quality and ensure competency. Validating new technology and proving its cost-effectiveness and effect on patient outcomes present the biggest challenge to IP as the health-care environment marches toward value-based health care. High-quality research is now thriving in IP and promises to elevate its practice into patient-centric evidence-based care.",
keywords = "bronchoscopy, interventional pulmonology, lung biopsy, lung neoplasm",
author = "Wahidi, {Momen M.} and Herth, {Felix J.F.} and Alexander Chen and George Cheng and Lonny Yarmus",
note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. M. W. has served as a consultant to Boston Scientific; Nuvaira Inc; Olympus Corporation; and Veracyte, Inc and has served as a reviewer on the Data Safety Monitoring Board for CSA Medical Inc. F. J. F. H. has served as a consultant to Broncus Medical, Inc; BTG plc; Olympus Corporation; Pulmonx Inc; and Uptake Medical and has received research funding from them. A. C. has served as a consultant to Auris Health, Inc; Boston Scientific; and Olympus Corporation and has received research funding from Auris Health, Inc; Boston Scientific ; Olympus Corporation; and Veran Medical Technologies. G. C. has served as a consultant to Boston Scientific; Medtronic plc; Pinnacle Biologics, Inc; and Restor3D and has received research funding from Intuitive Surgical Inc and Pinnacle Biologics, Inc. L. Y. has served as a consultant to AstraZeneca; Boston Scientific; Olympus Corporation; Veracyte, Inc; and Veran Medical Technologies. Publisher Copyright: {\textcopyright} 2019 American College of Chest Physicians",
year = "2020",
month = mar,
doi = "10.1016/j.chest.2019.10.013",
language = "English (US)",
volume = "157",
pages = "724--736",
journal = "CHEST",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",
}